

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7730878

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
IL DONG PHARMACEUTICAL CO., LTD.	12/09/2022
RECEIVING PARTY DATA	
Name:	ILDONG BIOSCIENCE CO., LTD.
Street Address:	17, POSEUNGGONGDAN-RO, POSEUNG-EUP
Internal Address:	PYEONGTAEK-SI
City:	GYEONGGI-DO
State/Country:	KOREA, REPUBLIC OF
Postal Code:	17957
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	11268064
CORRESPONDENCE DATA	
Fax Number:	(312)346-8434
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(312) 476-7566
Email:	patents@lplegal.com
Correspondent Name:	LEVENFELD PEARLSTEIN, LLC
Address Line 1:	2 N. LASALLE STREET
Address Line 2:	SUITE 1300
Address Line 4:	CHICAGO, ILLINOIS 60602
ATTORNEY DOCKET NUMBER:	41581-106125WO.USDIV
NAME OF SUBMITTER:	SUN Y. PAE
SIGNATURE:	/Sun Y. Pae/
DATE SIGNED:	01/09/2023
Total Attachments: 2	
source=OP19-0109_DIV_US-2023-01-09-Assignment (executed) (16125WO.USDIV)#page1.tif	
source=OP19-0109_DIV_US-2023-01-09-Assignment (executed) (16125WO.USDIV)#page2.tif	

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("ASSIGNMENT") is effective as of December 9th, 2022 and is by and between **IL DONG PHARMACEUTICAL CO., LTD.**, a Korean entity, having an address at Yangjae-dong) 2, Baumnok-ro 27-gil, Seocho-gu, Seoul 06752, Republic of Korea ("Assignor"), and **ILDONG BIOSCIENCE CO., LTD.**, a Korean entity, having an address at 17, Poseunggongdan-ro, Poseung-eup, Pyeongtaek-si, Gyeonggi-do 17957 Republic of Korea ("Assignee").

WHEREAS, Assignor is the sole and exclusive owner of U.S. Patent 11,268,064 for LACTOBACILLUS RHAMNOSUS RHT-3201 CONJUGATED TO POLYSACCHARIDE POLYMER BINDER, AND USE THEREOF FOR PREVENTION OR TREATMENT OF ATOPIC DISEASES, issued on March 8, 2022, from US Patent Application Serial No. 16/564,793 filed September 9, 2019 ("the '064 Patent");

WHEREAS, Assignor has agreed to sell, assign, and transfer the '064 Patent to Assignee.

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for and in consideration of ten dollars (\$10.00), and other valuable and legally sufficient consideration, the receipt and legal sufficiency of which are hereby acknowledged, Assignor has sold, assigned and transferred, and by these presents does hereby sell, assign and transfer unto Assignee: Assignor's entire right, title and interest in and to the '064 Patent and the inventions disclosed in the '064 Patent, including but not limited to patents, patent applications, patent registrations and patent interests of every kind and nature in and to the '064 Patent (and the right to apply for the foregoing), whether currently in force or obtained hereafter, which are owned, possessed and/or controlled by Assignor, in the United States, including the rights herein being transferred to Assignee; any and all renewals, extensions, continuations, continuations-in-part, divisions and reissues thereof that may be secured under all laws now or hereafter in force; any and all patents and patent applications upon which the priority of any of the foregoing is based, or which claim priority to any of the foregoing; all rights to causes of action or remedies related to the any of the foregoing (including the right to sue for past, present, or future infringement, misappropriation or violation of rights related to the foregoing, and the right to collect any and all damages arising from such infringement, misappropriation or violation of rights); any and all causes of action heretofore accrued in Assignor's favor for infringement of any of the foregoing; and, any and all other rights and interests arising out of, in connection with, or in relation to the foregoing; all for Assignee's use and enjoyment, and the use and enjoyment of Assignee's successors, assigns and legal representatives, for the full term and to the full extent of all such rights, and as fully and entirely as the same would have been held by Assignor had this assignment not been made.

AND, Assignor, for itself and its successors, assigns and legal representatives, hereby covenants and agrees that at any time, and from time to time forthwith upon the request of Assignee, Assignor will do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered, all such further acts, deeds, instruments, transfers and assurances as may be reasonably required by Assignee and Assignee's successors, assigns and legal representatives in order to assign, transfer, set over and convey unto, and vest in Assignee and Assignee's successors, assigns and legal representatives all rights sold, assigned and transferred herein, and to put Assignee and Assignee's successors, assigns in actual possession and operating control thereof, free and clear of all liens and encumbrances, to assure Assignee and Assignee's successors, assigns and legal representatives of the full benefits thereof. This ASSIGNMENT shall be binding upon and shall inure to the benefit of the respective successors, assigns and legal representatives of Assignor and Assignee.

IN WITNESS WHEREOF, the parties hereto have caused this ASSIGNMENT to be executed by their respective duly authorized officers effective as of the above-written date.

ASSIGNOR:

IL DONG PHARMACEUTICAL CO., LTD.

By: Paul W. Jun / JUN
PAUL W. JUN

Its: President and CEO

ASSIGNEE:

ILDONG BIOSCIENCE CO., LTD.

By: J. H. Lee / Jam Hyey Lee

Its: CEO